Rhythm Pharmaceuticals amends sales agreement to allow up to $200M in at-the-market stock offerings

RHYTHM PHARMACEUTICALS, INC.

Amendment increases ATM offering limit from $100M to $200M, excluding $50M already sold.
Company had $50M in prior sales as of Feb 29, 2024; new capacity starts from zero.
No specific use of proceeds disclosed; typical for general corporate purposes.

item 1.01 item 9.01

RHYTHM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-029417

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.